Not a good buy right now (for an impatient buyer): the stock is in a confirmed downtrend (bearish MA stack + negative MACD), and there’s no Intellectia buy signal to override that.
Near-term risk > near-term reward: price is below the key pivot (112.376) and only ~2.6% above first support (105.798), so downside to support is still in play before a cleaner entry.
Sentiment is mixed: options positioning is modestly call-leaning, but Wall Street just reset expectations (multiple target cuts) after a guide disappointment.
Congress activity is a red flag: 4 sells / 0 buys in the last 90 days adds to the “don’t chase now” case.
Volatility: 30D IV 22.44 vs historical vol 17.02 → options are pricing in elevated movement (premium relatively rich).
Activity: Today’s volume 3426 is only ~42.85% of 30-day average volume → sentiment read is not backed by heavy flow.
Open interest: Calls OI 119,159 vs puts OI 98,859 supports the mild bullish skew, but it’s not extreme.
Technical Summary
Sell
6
Buy
4
Positive Catalysts
MedTech strength: Medical device division reported +12.3% sales growth; diabetes care +14.5% YoY, supporting the core growth narrative.
Potential strategic catalyst: Plan to acquire Exact Sciences (~$21B) to bolster diagnostics (could re-rate sentiment if integration thesis is well-received).
Dividend support: Long dividend-growth history (50 consecutive years mentioned) and ~2.4% yield narrative attracts defensive capital in weak tape.
If headwinds abate: Several analysts expect nutrition/diagnostics challenges to stabilize through 2026, which could restore confidence later.
Freedom Capital: Upgraded to Buy (PT $130→$120) citing pullback and longer-term setup.
Wall Street pros: durable MedTech growth engine, potential pipeline/product launches, expectation that diagnostics headwinds ease.
Wall Street cons: nutrition weakness and softer near-term outlook; stock likely needs “better quarters” before momentum returns.
People Also Watch
Wall Street analysts forecast ABT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABT is 148.11 USD with a low forecast of 136 USD and a high forecast of 169 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
Wall Street analysts forecast ABT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABT is 148.11 USD with a low forecast of 136 USD and a high forecast of 169 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Buy
2 Hold
0 Sell
Strong Buy
Current: 109.080
Low
136
Averages
148.11
High
169
Current: 109.080
Low
136
Averages
148.11
High
169
Barclays
Overweight
to
NULL
downgrade
$169 -> $142
AI Analysis
2026-02-02
Reason
Barclays
Price Target
$169 -> $142
AI Analysis
2026-02-02
downgrade
Overweight
to
NULL
Reason
Barclays lowered the firm's price target on Abbott to $142 from $169 and keeps an Overweight rating on the shares. The firm cites its reduced estimates and a lower target multiple following the company's outlook for the target cut. It expects Abbott's challenges in nutrition and diagnostics to stabilize throughout 2026.
Freedom Capital
Hold
to
Buy
upgrade
$130 -> $120
2026-01-29
Reason
Freedom Capital
Price Target
$130 -> $120
2026-01-29
upgrade
Hold
to
Buy
Reason
Freedom Capital upgraded Abbott to Buy from Hold with a price target of $120, down from $130. The firm cites long-term prospects of the company's Exact Sciences integration and the significant pullback in the shares for the upgrade.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ABT
